Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Teverelix DP · 2 trials · 4 indications
Percent change from baseline in total prostate volume as assessed by transrectal ultrasound.
Castration rate defined as the cumulative probability of testosterone suppression to \< 0.5 ng/mL with the lower bound of the 95% confidence interval (CI) being \> 90%
| Arm | Type | Description |
|---|---|---|
| Teverelix DP 90 mg IM | ACTIVE_COMPARATOR | - |
| Teverelix DP 120 mg SC | ACTIVE_COMPARATOR | - |
| Teverelix DP placebo 90 mg IM | PLACEBO_COMPARATOR | - |
| Teverelix DP placebo 120 mg SC | PLACEBO_COMPARATOR | - |
| Teverelix DP 180 mg | EXPERIMENTAL | Participants receive teverelix DP loading dose on Day 1 (180 mg IM + 2x 180 mg SC) then teverelix DP 2x 180 mg SC on Day 29 and every 6 weeks to Week 16 (Day 113) |
| Name | Type | Description |
|---|---|---|
| Teverelix DP | DRUG | Single dose at Day 1 of 90 mg injection IM |
| Teverelix DP Placebo | DRUG | Single dose at Day 1 of 90 mg injection IM |
| Teverelix DP 180 mg | DRUG | Teverelix DP 540 mg Day 1 and 360 mg every 6 weeks from week 4 to week 16. |
Inclusion Criteria: 1. Male aged 45 years or older 2. Having given his written consent 3. Successful TWOC as defined by successful voiding with a minimum residual volume 4. Having had a first episode of spontaneous acute urinary retention within 6 days of study screening visit. 5. Prostate volume \...
Top 20 of 54 competitors
Teverelix DP is an investigational small molecule being developed for advanced prostate cancer and acute urinary retention. It is a gonadotropin-releasing hormone (GnRH) antagonist under evaluation in Phase 2 clinical trials for these urology-related conditions.
Teverelix DP targets the gonadotropin-releasing hormone (GnRH) receptor. As a GnRH antagonist, it is designed to block the action of GnRH, which is involved in the hormonal pathways relevant to prostate cancer and urinary retention.
Teverelix DP is being developed by Medicus Pharma Ltd., a company listed on the stock exchange under the ticker MDCX. The company is conducting Phase 2 clinical trials to evaluate the drug's safety and efficacy.
Teverelix DP is in Phase 2 clinical development. It is an investigational drug, not yet approved by regulatory authorities. Two Phase 2 trials are planned but have not yet started recruiting participants.
Teverelix DP is involved in two Phase 2 clinical trials. NCT07457164 studies its pharmacokinetics, pharmacodynamics, efficacy, and safety in advanced prostate cancer with 40 participants. NCT07733934 evaluates its effects on prostate volume and urinary function following acute urinary retention with 126 participants.
Yes, Teverelix DP is also known as Teverelix DP 180 mg. This alternative name refers to the same drug product, which is being investigated for advanced prostate cancer and acute urinary retention.